Previous 10 | Next 10 |
Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant Update...
Gainers: Avadel Pharmaceuticals (AVDL) +30%. AgeX Therapeutics (AGE) +9%. Helius Medical Technologies (HSDT) +7%. Quipt Home Medical (QIPT) +7%. Gamida Cell (GMDA) +5%. Losers: Protagonist Therapeutics (PTGX) -47%. Nkarta (NKTX) -14%. ...
Penny stocks have earned their place in the stock market today for their high-risk & high-reward reputation. But something that most new traders fail to realize is that these cheap stocks aren’t just “lottery tickets” to buy blindly. There are plenty of ways to make...
Jiuzi Holdings (JZXN) +88% enters into an equity acquisition agreement to acquire automobile sales serviceshop operator under top China automaker Geely Auto's premium electronic vehicle brand geometry. Avadel Pharmaceuticals (AVDL) +35% provides comment on Recent trading activity. Gamida...
Gamida Cell (NASDAQ:GMDA) said the U.S. Food and Drug Administration (FDA) lifted a clinical hold for a cryopreserved formulation of GDA-201. The company added that the FDA cleared its investigational new drug (IND) application to start a trial of its NK cell therapy candidate GDA-2...
Company advancing plans to begin Phase 1/2 study in patients with follicular and diffuse large B-cell lymphomas Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious dise...
Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant Oral p...
Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant Study ...
Shares of Gamida Cell Ltd. (NASDAQ:GMDA) traded today at $17.89, eclipsing its 52-week high. This new high was reached on above average trading volume as 24 million shares traded hands, while the average 30-day volume is approximately 310,000 shares. Gamida Cell Ltd. has overhead space w...
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, announced that company management will present at the upcoming 21 st Annual Needham Virtual Healthcare Conferenc...
News, Short Squeeze, Breakout and More Instantly...
Gamida Cell Ltd. Company Name:
GMDA Stock Symbol:
NASDAQ Market:
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...
2024-04-03 06:21:00 ET How to Analyze Different Penny Stocks Sectors to Make Money Investing in penny stocks offers an accessible entry point for individuals aiming to participate in the stock market with a lower initial investment. Analyzing different sectors within the realm of penn...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 43.8% to $0.1485 on volume of 202,621,744 shares Nikola Corporation (NKLA) fell 5.5% to $0.9736 on volume of 187,304,976 shares C3is Inc. (CISS) rose 13.3% to $0.0409 on volume of 136,767,990 shares ...